Question explored with the scientific record
Will ivermectin help lymphoma?
The short version: ivermectin has shown anti-cancer activity in lab dishes and animal models, but no human trial has tested it against lymphoma.
The evidence you retrieved is all pre-clinical. One 2020 review lists ivermectin as having activity against "lymphoma lines" in a petri dish, along with mechanisms like blocking AKT/mTOR and Wnt signaling and reducing cancer stem cell markers [12]. A 2015 study on breast cancer cells found ivermectin kills cancer cells by flooding them with calcium and triggering an inflammatory form of cell death through P2X4/P2X7 channels [11]. A 2016 study on glioblastoma showed it stops tumor growth in mice by damaging mitochondria and suppressing the same AKT/mTOR pathway [14]. A 2019 glioma study confirmed it triggers autophagy through that pathway [13].
None of these are lymphoma. None are human trials. The doses that kill cancer cells in a dish (IC50 around 2-5 micromolar) are far above what a standard oral dose of ivermectin reaches in human blood without toxicity [6]. The 2025 COVID review notes that pharmacokinetic arguments suggest the needed concentrations are "unachievable in vivo at safe doses" [6].
| Evidence type | What it shows | Relevance to human lymphoma |
|---|---|---|
| Cell-line studies (breast, glioma, leukemia) | Ivermectin kills cancer cells at 2-5 µM via multiple pathways [11, 13, 14] | Mechanism plausible, dose question unanswered |
| 2020 narrative review | Lists "lymphoma lines" as sensitive in vitro [12] | No details, no human data |
| COVID repurposing review | Notes ivermectin's in vivo concentrations may be too low for anti-cancer effect [6] | Directly relevant to feasibility |
My call: ivermectin is not a proven treatment for lymphoma. The pre-clinical mechanism is interesting but the dose needed to kill cancer cells probably cannot be reached safely in a human. Confidence: low that it helps, moderate that the evidence does not support using it now.
Sources examined 14
-
Male songbirds show higher coccidia oocyst burdens than females following anthelmintic treatment
The study shows that two-dose ivermectin treatment increases coccidia oocyst burden in male wild-caught dark-eyed juncos held in captivity, while females show no such increase, highlighting sex-specific responses to antiparasitic treatment and implications for quarantine practic…
DOI: 10.64898/2025.12.12.694047 -
The immunomodulatory effect of ivermectin on rat vasculitis model
Ivermectin pretreatment reduces inflammatory markers and Toll-like receptor 4 expression in ovalbumin/LPS-induced rat vasculitis, indicating an immunomodulatory protective effect against vascular inflammation.
DOI: 10.34172/ipp.2025.42741 -
Effect of Moringa oleifera and ivermectin nanoparticles on the immunopathological response during experimental trichinosis in mice
A murine Trichinella spiralis infection model was used to test nanoparticle formulations of ivermectin (IVM-NP) and Moringa oleifera leaf extract (MOL-NP), alone and in combination, showing that co-treatment more effectively reduces parasite burden and modulates macrophage-relat…
DOI: 10.1186/s13099-025-00764-7 -
Application of the Analysis of Serum Antibodies (Immunoglobulins M and G) to Estimate the Seroprevalence of Ovine Oestrosis and to Evaluate the Effect of Chemotherapy
The study uses ELISA-based serology against Oestrus ovis L2 excretory/secretory antigens to map seasonal IgM/IgG seroprevalence of ovine oestrosis in sheep from an oceanic climate area of northwestern Spain and to evaluate the effect of ivermectin chemotherapy on humoral respons…
DOI: 10.1603/ME09228 -
Biochemical autoregulatory gene therapy for focal epilepsy
The study develops a biochemical autoregulatory gene therapy using a glutamate-gated chloride channel (eGluCl) under a CaMKIIα promoter, packaged in a lentivector, which silences excitatory neurons in response to elevated extracellular glutamate and demonstrably reduces both acu…
DOI: 10.1038/s41591-018-0103-x -
COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose–That Was the Question
This article critically reviews COVID-19 drug repurposing with a focus on hydroxychloroquine, ivermectin, and remdesivir, outlining the evidence, controversies, regulatory responses, and ongoing debates about their efficacy, safety, and scientific integrity.
DOI: 10.3390/v17070881 -
Reproductive Status of Onchocerca volvulus after Ivermectin Treatment in an Ivermectin-Naïve and a Frequently Treated Population from Cameroon
Embryostatic effect of ivermectin on Onchocerca volvulus persists after 13 years of frequent treatment but is reduced compared with ivermectin-naïve individuals, consistent with earlier skin mf repopulation in the frequently treated cohort.
DOI: 10.1371/journal.pntd.0002824 -
PGP expression in Cooperia oncophora before and after ivermectin selection
This study investigates genetic selection and P-glycoprotein (Con-pgp-9) expression in Cooperia oncophora isolates before and after ivermectin treatment, finding no significant overall changes in Con-pgp-9 expression post-treatment, no bottleneck or differentiation in AFLP analy…
DOI: 10.1007/s00436-013-3473-5 -
Synaptic and neural pathway redundancy enables the robustness of a sensory-motor reflex and promotes predation escape in C. elegans
This study maps the molecular and developmental basis of redundant neural connections in the C. elegans touch reflex, revealing multi-level redundancy across neural pathways, synapses, and gap junctions that ensures robust sensory-motor responses and predator-escape behaviors, i…
DOI: 10.1101/2025.09.18.677212 -
Food Supplementation Reduces Nematode Super-Shedding in a Wild Mammal
Three-year field experiment across twelve bank vole populations revealed that food provisioning reduces abundance super-shedding without affecting overall nematode prevalence or burden, while anthelmintic treatment lowers both prevalence and abundance super-shedding, and nematod…
DOI: 10.64898/2026.01.16.699562 -
Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death
Augmenting extracellular ATP signaling through P2X4/P2X7/Pannexin-1 with Ivermectin drives a rapid, inflammatory cancer cell death in breast cancer cells, combining necrotic/pyroptotic and apoptotic pathways via ROS/CaMKII/MPTP and autophagy, with immunogenic-cell-death hallmark…
DOI: 10.1038/srep16222 -
Old wine in new bottles: Drug repurposing in oncology
A comprehensive narrative review detailing how eight non-oncologic drugs (artesunate, aspirin, cimetidine, doxycycline, ivermectin, metformin, rapamycin, and thalidomide) have demonstrated anticancer activity across in vitro, in vivo, and limited clinical contexts, outlining the…
DOI: 10.1016/j.ejphar.2019.172784 -
Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells
Ivermectin triggers autophagy through AKT/mTOR inhibition in glioma cells; autophagy protects against IVM-induced apoptosis in vitro, and combining with chloroquine enhances anti-glioma effects in vivo.
DOI: 10.1042/bsr20192489 -
Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress
Ivermectin, a repurposed antiparasitic, inhibits glioblastoma cell growth and angiogenesis by inducing mitochondrial dysfunction and oxidative stress, while concurrently suppressing the Akt/mTOR signaling axis in tumor and endothelial cells, with supporting in vivo xenograft dat…
DOI: 10.1016/j.bbrc.2016.10.064